TY - JOUR
T1 - Common drug pipelines for the treatment of diabetic nephropathy and hepatopathy
T2 - Can we kill two birds with one stone?
AU - Japan Study Group of NAFLD (JSG-NAFLD)
AU - Sumida, Yoshio
AU - Yoneda, Masashi
AU - Toyoda, Hidenori
AU - Yasuda, Satoshi
AU - Tada, Toshifumi
AU - Hayashi, Hideki
AU - Nishigaki, Yoichi
AU - Suzuki, Yusuke
AU - Naiki, Takafumi
AU - Morishita, Asahiro
AU - Tobita, Hiroshi
AU - Sato, Shuichi
AU - Kawabe, Naoto
AU - Fukunishi, Shinya
AU - Ikegami, Tadashi
AU - Kessoku, Takaomi
AU - Ogawa, Yuji
AU - Honda, Yasushi
AU - Nakahara, Takashi
AU - Munekage, Kensuke
AU - Ochi, Tsunehiro
AU - Sawada, Koji
AU - Takahashi, Atsushi
AU - Arai, Taeang
AU - Kogiso, Tomomi
AU - Kimoto, Satoshi
AU - Tomita, Kengo
AU - Notsumata, Kazuo
AU - Nonaka, Michihiro
AU - Kawata, Kazuhito
AU - Takami, Taro
AU - Kumada, Takashi
AU - Tomita, Eiichi
AU - Okanoue, Takeshi
AU - Nakajima, Atsushi
N1 - Funding Information:
Funding: This research was funded by Grant Number JP20fk0210040 and The APC was funded by Grant Number JP20fk0210040.
Funding Information:
Acknowledgments: This study was supported by all members of Japan Strategic Medical Administration Research Center (J-SMARC).
Funding Information:
Conflict of Interest: Y.S. (Yoshio Sumida) received honoraria from Mitsubishi Tanabe, Sumitomo Dainippon, Astrazeneka, Ono, and Taisho pharm. Y.S. (Yoshio Sumida) received research funding from Bristol-Meyers Squibb. H.T. (Hidenori Toyoda) received honoraria from Gilead Sciences and AbbVie. N.K. received research funding from AbbVie. H.T. (Hiroshi Tobita) received research funding from AstraZeneca K.K. and Ono Pharmaceutical Co., Ltd. A.N. received honoraria from Gilead, Bristol-Meyers Squibb, Novartis, and EA pharma. A.N. received research funding from EA pharma, Mylan, and EPD. The other co-authors declare no conflict of interest.
PY - 2020/7/2
Y1 - 2020/7/2
N2 - Type 2 diabetes (T2D) is associated with diabetic nephropathy as well as nonalcoholic steatohepatitis (NASH), which can be called “diabetic hepatopathy or diabetic liver disease”. NASH, a severe form of nonalcoholic fatty disease (NAFLD), can sometimes progress to cirrhosis, hepatocellular carcinoma and hepatic failure. T2D patients are at higher risk for liver-related mortality compared with the nondiabetic population. NAFLD is closely associated with chronic kidney disease (CKD) or diabetic nephropathy according to cross-sectional and longitudinal studies. Simultaneous kidney liver transplantation (SKLT) is dramatically increasing in the United States, because NASH-related cirrhosis often complicates end-stage renal disease. Growing evidence suggests that NAFLD and CKD share common pathogenetic mechanisms and potential therapeutic targets. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and diabetic nephropathy/CKD. There are no approved therapies for NASH, but a variety of drug pipelines are now under development. Several agents of them can also ameliorate diabetic nephropathy/CKD, including peroxisome proliferator-activated receptors agonists, apoptosis signaling kinase 1 inhibitor, nuclear factor-erythroid-2-related factor 2 activator, C-C chemokine receptor types 2/5 antagonist and nonsteroidal mineral corticoid receptor antagonist. This review focuses on common drug pipelines in the treatment of diabetic nephropathy and hepatopathy.
AB - Type 2 diabetes (T2D) is associated with diabetic nephropathy as well as nonalcoholic steatohepatitis (NASH), which can be called “diabetic hepatopathy or diabetic liver disease”. NASH, a severe form of nonalcoholic fatty disease (NAFLD), can sometimes progress to cirrhosis, hepatocellular carcinoma and hepatic failure. T2D patients are at higher risk for liver-related mortality compared with the nondiabetic population. NAFLD is closely associated with chronic kidney disease (CKD) or diabetic nephropathy according to cross-sectional and longitudinal studies. Simultaneous kidney liver transplantation (SKLT) is dramatically increasing in the United States, because NASH-related cirrhosis often complicates end-stage renal disease. Growing evidence suggests that NAFLD and CKD share common pathogenetic mechanisms and potential therapeutic targets. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and diabetic nephropathy/CKD. There are no approved therapies for NASH, but a variety of drug pipelines are now under development. Several agents of them can also ameliorate diabetic nephropathy/CKD, including peroxisome proliferator-activated receptors agonists, apoptosis signaling kinase 1 inhibitor, nuclear factor-erythroid-2-related factor 2 activator, C-C chemokine receptor types 2/5 antagonist and nonsteroidal mineral corticoid receptor antagonist. This review focuses on common drug pipelines in the treatment of diabetic nephropathy and hepatopathy.
UR - http://www.scopus.com/inward/record.url?scp=85087799880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087799880&partnerID=8YFLogxK
U2 - 10.3390/ijms21144939
DO - 10.3390/ijms21144939
M3 - Review article
C2 - 32668632
AN - SCOPUS:85087799880
VL - 21
SP - 1
EP - 22
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 14
M1 - 4939
ER -